Nathan Higginson-Scott (Preferred)
Nathan Higginson-Scott
Chief Technology Officer, Drug Creation, Seismic Therapeutic
Joined
May 2024
Names
Emails
****@seismictx.com (Confirmed)
****@gmail.com
Personal Links
Career & Education History
Chief Technology Officer
Drug Creation, Seismic Therapeutic (seismictx.com)
2021 – Present
VP Biotherapeutics
Biotherapeutics, Pandion Therapeutics (pandiontx.com)
2017 – 2021
Principal Researcher
Global Biotherapeutic Technologies, Pfizer (pfizer.com)
2008 – 2017
Senior Scientist
Google Life Sciences / Verily, Google (google.com)
2014 – 2016
PhD student
Biochemistry, Imperial College London (imperial.ac.uk)
2005 – 2008
MS student
Biochemistry, Imperial College London (imperial.ac.uk)
2004 – 2005
Undergrad student
Life Sciences, University of Kent (kent.ac.uk)
2000 – 2004
Advisors, Relations & Conflicts
Expertise
machine learning
, AI
, drug discovery
, biotherapeutics
, structural biology
, autoimmunity
, inflammation
, enzymology
2021 – 2024
biotherapeutics
, drug discovery
, autoimmunity
, inflammation
, tissue targeting
, TRegs
2017 – 2021
antibody discovery
, antibody engineering
, bispecifics
, multispecifics
, ADCs
, pH switches
, tech development
2008 – 2017
phage display
, antibody engineering
, avidity and chelation dynamics
2004 – 2008